Overview

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

Status:
Completed

Trial end date:
2018-05-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetic (PK) profile of a fixed dose of SPI-2012 in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) chemotherapy, as measured by the serum concentration of SPI-2012 on specific days following drug administration.

Phase:

Phase 1

Details

Lead Sponsor:

Spectrum Pharmaceuticals, Inc

Treatments:

Cyclophosphamide
Docetaxel